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Anti-glutamatergic drugs can relieve Parkinson’s disease (PD) symptoms and decrease
l-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias (LID). This review reports rele-
vant studies investigating glutamate receptor subtypes in relation to motor complications
in PD patients and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mon-
keys. Antagonists of the ionotropic glutamate receptors, such as N -methyl-d-aspartate
(NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, dis-
play antidyskinetic activity in PD patients and animal models such as the MPTP monkey.
Metabotropic glutamate 5 (mGlu5) receptor antagonists were shown to reduce the severity
of LID in PD patients as well as in already dyskinetic non-human primates and to prevent
the development of LID in de novo treatments in non-human primates. An increase in
striatal post-synaptic NMDA, AMPA, and mGlu5 receptors is documented in PD patients
and MPTP monkeys with LID. This increase can be prevented in MPTP monkeys with the
addition of a specific glutamate receptor antagonist to the L-DOPA treatment and also with
drugs of various pharmacological specificities suggesting multiple receptor interactions.
This is yet to be well documented for presynaptic mGlu4 and mGlu2/3 and offers additional
new promising avenues.
Keywords: Parkinson’s disease, L-DOPA-induced dyskinesia, motor complications, glutamate receptor, basal
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INTRODUCTION
Parkinson’s disease (PD) is the most common neurodegenerative
movement disorder and is likely to increase due to the aging pop-
ulation (1). PD is principally attributed to the death of dopamine
(DA) neurons in the substantia nigra, but other neurotransmit-
ters, such as glutamate, are also affected (2). There is no cure for
PD but symptomatic treatments are available (3). Restoring lost
DA with its precursor, l-3,4-dihydroxyphenylalanine (l-DOPA),
remains the most effective treatment (4). However, many patients
(≥40%) develop motor complications after 5–10 years of treat-
ment (5). These motor complications include motor fluctuations
Abbreviations: 6-OHDA, 6-hydroxydopamine; Akt, protein kinase B; AMPA,
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; cAMP, cyclic adenosine
monophosphate; DA, dopamine; DARPP-32, DA and cAMP-regulated phospho-
protein with molecular weight 32; DHA, docosahexaenoic acid; ERK, extracellular-
signal-regulated kinase; GABA, γ-aminobutyric acid; GSK3, glycogen synthase
kinase-3; GP, globus pallidus; GPe, external globus pallidus; GPi, internal globus
pallidus; iGlu, ionotropic glutamate; KA, kainate; l-DOPA, levodopa (l-3,4-
dihydroxyphenylalanine); LID, l-DOPA-induced dyskinesias; MAPK, mitogen-
activated protein kinase; mavoglurant, AFQ056; mGlu, metabotropic glutamate;
MPEP, 2-methyl-6-(phenylethynyl)pyridine; MPTP, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine; MTEP, 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine; mTor,
mammalian target of rapamycin; NAM, negative allosteric modulator; NMDA, N -
methyl-d-aspartate; PD, Parkinson’s disease; PI3K, phosphoinositide 3-kinase; PKA,
protein kinase A; PP-1, protein phosphatase-1; STN, subthalamic nucleus; Wnt,
wingless/integrated-signaling.
and abnormal involuntary movements, such as l-DOPA-induced
dyskinesias (LID), and contribute to limit the quality of life in
PD patients and can be very difficult to manage (6). Motor fluc-
tuations such as “wearing-off” are also common. Wearing-off is
defined as a reduced duration of benefit from an individual l-
DOPA dose and a recurrence of parkinsonian symptoms before
the next normal dose of l-DOPA (7).
No drug is yet available for LID, aside from some benefit
with amantadine that has anti-glutamatergic properties (8). Glu-
tamatergic transmission is increased in the basal ganglia in PD (9)
and is also believed to be involved in LID (10, 11).
The mechanisms involved in the occurrence of LID are still not
fully understood, altered dopaminergic and non-dopaminergic
neurotransmission in the basal ganglia are observed in LID (12).
A recent strategy is to treat LID with adjunct drugs targeting
non-dopaminergic neurotransmitter systems such as glutamate
to indirectly modulate basal ganglia DA neurotransmission (13).
Glutamate is involved in many physiological functions through
its interactions with ionotropic glutamate (iGlu), ligand-gated
channel, and metabotropic G-protein-coupled glutamate (mGlu)
receptors. iGlu receptors drugs suppressing glutamate excitatory
transmission often create undesirable side effects (14), whereas
acting on mGlu receptors could lead to a more subtle and/or
circuit-selective modulation of excitatory transmission (15). Phar-
macologic characterization of metabotropic glutamate 5 (mGlu5)
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receptors and its selective negative allosteric modulators (NAMs)
show therapeutic potential in animal models of PD (16–18) and
efficacy in human PD (19, 20). While mGlu5 receptors regulate l-
DOPA-induced motor behavior, the mechanisms involved remains
to be fully elucidated (21).
This review focuses on relevant studies investigating glutamate
receptor subtypes in the pathophysiology of PD and LID. Brain
biochemical correlates of motor complications in PD patients and
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned
monkeys are reviewed.
GLUTAMATE NEUROTRANSMISSION IN THE BASAL
GANGLIA AND PARKINSON’S DISEASE
Glutamate is the brain’s most abundant excitatory neurotrans-
mitter mediating as much as 70% of synaptic transmission (22).
Amantadine reduces LID, it also improves akinesia, rigidity, and
tremor (3). The non-selective inhibitor of glutamate transmission
(riluzole) was shown to block l-DOPA-induced motor compli-
cations in 6-hydroxydopamine (6-OHDA) lesioned rat model of
PD (23, 24) and the glial glutamate transporter GLT1 is increased
in dyskinetic l-DOPA-treated 6-OHDA rats (25, 26). However,
riluzole was not effective in humans to relieve LID (27, 28).
LEVODOPA-INDUCED DYSKINESIAS AND NON-HUMAN
PRIMATE MODEL
l-DOPA-induced dyskinesias are abnormal involuntary move-
ments seen typically at the peak effect of each dose of l-DOPA
in PD patients (3). LID can be viewed quantitatively as an excess
of movement or qualitatively as a problem in selecting the appro-
priate motor program or pattern (3). The mechanisms involved in
the occurrence of LID are complex and have been investigated in
numerous studies using animal models and parkinsonian patients
(29). The loss of nigrostriatal DA and the chronic administra-
tion of l-DOPA, or DA agonists, are two necessary conditions for
their appearance (30). The development of LID in human usu-
ally requires daily treatment for 3–5 years in idiopathic PD (31),
whereas for parkinsonism induced by the toxin MPTP it occurs
after only weeks or months of treatment (32). The same applies
to the MPTP-lesioned monkey where l-DOPA is usually adminis-
tered daily for weeks before LID appear (33, 34). MPTP-lesioned
primates respond to DA therapies as idiopathic PD patients (35,
36) and are currently the best model for studying LID (37).
MPTP-lesioned primates are very useful to test potential anti-
dyskinetic and/or anti-parkinsonian pharmacological agents (37).
The primates are rendered parkinsonian and then chronically
treated with l-DOPA for several weeks or months until they
express stable and well-established LID. Then, acute or chronic
effects of compounds are tested when co-administered with l-
DOPA (17, 18, 38, 39). This model is widely used since it allows
rapid testing of new compounds and animals may be used for
several studies. This paradigm is useful to find new treatments for
advanced parkinsonian patients with already established LID (37).
Another paradigm uses de novo animals rendered parkinsonian
with MPTP and then treated with l-DOPA alone or in combina-
tion with the agent under investigation (37). This latter paradigm
allows the study of specific effects of the test compound on the
development of LID and to assess if the effects diminish with
long-term use, also called “wearing-off” (40–44). Furthermore,
it allows to investigate the post-mortem brains of these mon-
keys the mechanisms associated with the behaviors and relate it
to the specific treatments (42, 44–47). This experiment models
newly diagnosed parkinsonian patients when l-DOPA treatment
is initiated and could be used to test adjunct drugs to l-DOPA to
avoid development of LID while having a good anti-parkinsonian
effect (37). Docosahexaenoic acid (DHA) and cabergoline were
shown to reduce the severity or delay the development of LID in
MPTP-lesioned monkey (41, 48).
IONOTROPIC GLUTAMATE RECEPTORS AND
LEVODOPA-INDUCED DYSKINESIAS
Ionotropic glutamate receptors mediate fast excitatory neuro-
transmission, whereas mGlu receptors mediate slower mod-
ulatory neurotransmission. iGlu receptors are classified into
N -methyl-d-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA), and kainate (KA) receptors
(49). An increase in striatal NMDA and AMPA receptor binding
levels in PD patients with l-DOPA-induced motor complica-
tions (11) and dyskinetic MPTP monkeys was observed (50, 51).
Moreover, NMDA and AMPA receptor antagonists block the devel-
opment of l-DOPA-induced motor complications in 6-OHDA
rats (23). The NMDA antagonist, CI-1041 can prevent the devel-
opment of LID in parkinsonian monkeys (40), and associated
brain molecular changes (52). In these monkeys, CI-1041 also pre-
vented the increased of striatal mGlu5 receptor levels (53). Clinical
trials show the antidyskinetic profile of amantadine, known to
block NMDA receptors (8, 54, 55). Kynurenic acid antagonizes
glycine b site of NMDA receptors, AMPA, and KA receptors (56,
57) and inhibits glutamate release (58). RO 61-8048, an inhibitor
of kynurenine hydroxylase activity, can increase kynurenic acid
levels (59); it acutely reduced dyskinesias in MPTP monkeys
with LID (60) and reduced their development in de novo treated
MPTP monkeys (61). Abundant recent literature focused on the
role of NMDA and AMPA receptor subunits in rodent and non-
human primate models of PD in LID including the glycine site,
NMDA GluN2D subunits, AMPA receptor subunit composition,
and NMDA/AMPA receptor ratio (49, 62–66). Nevertheless, iGlu
receptors can cause significant adverse effects such as cognitive
impairment in many patients (67, 68).
METABOTROPIC GLUTAMATE RECEPTORS AND
LEVODOPA-INDUCED DYSKINESIAS
Metabotropic glutamate receptors are divided into Group I
(mGlu1, 5) coupling to Gq and promoting polyphosphoinositide
hydrolysis, Group II (mGlu2, 3) and III (mGlu4, 6, 7, 8) coupling to
Gi/Go and inhibiting Forskolin-induced increase in cyclic adeno-
sine monophosphate (cAMP) (69). All mGlu receptors are present
in the brain basal ganglia except mGlu6 receptor found primarily
in the retina (70). The majority (>90%) of Group I mGlu receptor,
including mGlu5, are located postsynaptically on the perisynaptic
annulus of dendritic spines (71). Presynaptically localized Group II
and Group III mGlu receptors are thought to represent the classical
inhibitory autoreceptor mechanism suppressing excess glutamate
release from presynaptic terminals (72).
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The prototypal mGlu5 receptor antagonist, 2-methyl-6-
(phenylethynyl)pyridine (MPEP) and a more selective ana-
log 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) (73)
improve motor performance (74) and show antidyskinetic activ-
ity in 6-OHDA rats (75, 76), but not the other Group I mGlu
receptor, such as mGlu1 receptor drugs (77, 78). mGlu5 receptor
levels were increased in the putamen of dyskinetic compared to
non-dyskinetic MPTP monkeys (42) and parkinsonian patients
with motor complications (LID or wearing-off) compared to
those without motor complications (53). MPEP and MTEP were
shown to have antidyskinetic activity in MPTP monkeys (17) and
the mGlu5 receptor antagonist mavoglurant (AFQ056) in MPTP
monkeys (18) and humans (19). We reported that development
of LID over a month of treatment were lower by overall ~70%
with addition of MPEP to the l-DOPA treatment in de novo
MPTP monkeys (44) and this was associated with a normaliza-
tion of glutamate (46) and DA neurotransmission (47). Similarly,
chronic administration of fenobam to drug-naïve monkeys atten-
uated the development of dyskinesia without compromising the
anti-parkinsonian effect of l-DOPA (43).
Group II mGlu receptor agonists have proven effective in ani-
mal models of PD (79). A decrease in mGlu2/3 receptor density
in dyskinetic compared to non-dyskinetic MPTP-lesioned mon-
keys was observed (46). In post-mortem brains of parkinsonian
patients, changes in mGlu2/3 receptors were only observed in
relation to wearing-off (80).
Recently,agonists of Group III receptors have shown robust effi-
cacy in rodent models of PD (70). mGlu4 receptor agonists reduce
γ-aminobutyric acid (GABA)ergic transmission at striatopallidal
synapse that is overactive in PD (81, 82). In 6-OHDA-lesioned
rats, a combined treatment with l-DOPA and the mGlu4 receptor
agonist Lu AF21934 reduced the effective dose of l-DOPA and
minimizing the development of LID (83).
Metabotropic glutamate 8 receptor is expressed at lower levels
than mGlu4 and mGlu7 receptors but widely distributed in the
brain; mGlu7 receptor has low affinity for glutamate only becom-
ing active when glutamate levels are high thus serving as a brake
for glutamate overstimulation (70). AMN082, an mGlu7 receptor
agonist, was shown to reverse motor dysfunction associated with
reduced DA activity in rodent models (84). However, the contri-
bution of mGlu7 and mGlu8 receptors in LID is not yet reported.
DISCUSSION
Denervation-induced supersensitivity of DA receptors is generally
recognized as a plausible mechanism of LID. Post-mortem stud-
ies have shown that DA receptors, particularly D2 subtype, are
increased in the striatum of parkinsonian patients (85–87) as well
as D1 and D2 receptors in MPTP monkeys (33, 34, 88, 89). How-
ever, treatment with l-DOPA can reverse this increase in humans
(85, 87) and monkeys (34, 88, 90). LID are clearly more com-
plex than hypersensitivity due to a simple increase in the density
of striatal DA receptors (30), hence changes are sought in signal-
ing pathways activated by DA receptors. Various adjunct drugs
that can modulate basal ganglia dopaminergic neurotransmission
have been shown to treat LID (13, 67, 91–94). Glutamate recep-
tors are reported to interact with numerous neurotransmitters and
neuromodulators implicated in the development of LID including
dopaminergic neurotransmission (22, 47). Hence, close interac-
tions are described between mGlu5 and NMDA receptors, mGlu5
with D2 receptors, and adenosine A2A receptors (39, 46, 47, 95,
96). Figure 1 shows interactions of striatal DA, adenosine, gluta-
mate and opioids in GABAergic neurons and possible sequence of
events leading to LID.
Dopamine receptors are associated with regulation of cAMP–
protein kinase A (PKA) through G-protein mediated signaling
(97). Downstream from PKA, DA, and cAMP-regulated phos-
phoprotein with molecular weight 32 (DARPP-32) has important
functions in regulating DA receptor signaling and its integra-
tion with other signaling modalities (98). Extracellular-signal-
regulated-kinase (ERK) is also an important mediator of cAMP
signaling involved in responses to DA drugs and might be
involved in the development of LID (99–101). Rats with abnor-
mal involuntary movements have abnormally high levels of stri-
atal phospho[Thr34]-DARPP-32 (102). DA receptors also exert
their effect through protein kinase B (Akt) and glycogen syn-
thase kinase-3 (GSK3) signaling (97) that might serve to integrate
signaling of different receptors such as glutamate. Akt can phos-
phorylate GSK3β at Ser9 [pGSK3β(Ser9)] and inactivate it (103).
GSK3 is a juncture of at least three pathways, mitogen-activated
protein kinase (MAPK) (104), phosphoinositide 3-kinase (PI3K)
(105), and wingless/integrated-signaling (Wnt) (106). Prolonged
stimulation of D2 DA receptors in rodents leads to specific
dephosphorylation/inactivation of striatal Akt on Thr308 residue
[pAkt(Thr308)], Ser473 [pAkt(Ser473)], remaining unaffected
(107). Another downstream protein is mammalian target of
rapamycin (mTor) recently reported to be implicated in LID (108).
D1 receptor supersensitive response was shown to result from a
switch from normal activation of the PKA cascade to aberrant acti-
vation of ERK1/2–MAP kinase in lesioned striata and is suggested
to underlie LID (109). Interestingly, in a chronic de novo treatment
with non-human primates, we observed increases in both striatal
pERK1/ERK1 and pERK2/ERK2 ratios of l-DOPA-treated MPTP
monkeys whereas MPEP prevented this increase (47). Moreover,
there were positive correlations between mean dyskinetic scores
and striatal pERK1/ERK1 and pERK2/ERK2 ratios (47). These
results suggest that antagonists of mGlu5 receptor can potentially
inhibit the excessive striatal activation of nuclear signaling path-
ways and gene expression that is produced by l-DOPA, which
might be related to the interaction with DA receptors.
An association between Akt1 gene and PD was also shown
(110). In post-mortem substantia nigra, a large reduction of
pAkt(Thr308) and pAkt(Ser473) in PD patients was observed
compared to controls (111). l-DOPA-treated MPTP monkeys
with LID show elevated pAkt(Ser473) and pGSK3β(Ser9) whereas
MPTP monkeys treated with l-DOPA+ cabergoline with no LID
have lower values (112). In MPTP-lesioned monkeys treated with
l-DOPA+CI-1041 that did not develop LID, changes in Akt
and GSK3 were modest suggesting implication of other path-
ways, such as ERK. As in the substantia nigra of parkinsonian
patients (111), we observe decreases of striatal pAkt with the
MPTP lesion in monkeys (112) whereas in 6-OHDA rats, the
lesion did not change or increased phosphorylation of Akt (Ser473
and Thr308) (113). In 6-OHDA rats, pGSK3α and pGSK3β were
also unchanged or increased with the lesion (113) while we
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FIGURE 1 | Schematic representation of L-DOPA (metabolized into DA)
and DA agonist treatments on striatal DA neurotransmission,
interactions of striatal DA, adenosine, glutamate, and opioids in
GABAergic neurons and possible sequence of events leading to LID.
Numerous interactions are known and are not all included; the focus of this
figure is on PI3K and MAPK pathways. A2A, adenosine A2A receptor; Akt,
protein kinase B; BAD, Bcl-2-associated death promoter; Bcl-2, B-cell
lymphoma 2; Ca2+, calcium ion; cAMP, cyclic adenosine monophosphate;
D1/D2/D3, D1/D2/D3 DA receptor; DA, dopamine; DARPP-32, DA and
cAMP-regulated phosphoprotein with molecular weight 32; DAG,
diacylglycerol; ERK, extracellular-signal-regulated kinase; GSK3, glycogen
synthase kinase-3; IGF-IR, type 1 insulin-like growth factor receptor; IP3,
inositol 1,4,5-trisphosphate; L-DOPA, levodopa (L-3,4-dihydroxyphenylalanine);
MEK, mitogen-activated protein kinase; mGlu5, metabotropic glutamate type
5 receptor; mTor, mammalian target of rapamycin; NMDA,
N -methyl-d-aspartate receptor; PI3K, phosphoinositide 3-kinase; PKA, protein
kinase A; PKC, protein kinase C; PLC, phospholipase C; Ras, proto-oncogene
protein p21; Raf, proto-oncogene serine/threonine-protein kinase; RTK,
receptor tyrosine kinases; Tau, microtubule-associated protein tau; TRK,
tropomyosin receptor kinase.
observed no change or decreases in MPTP monkeys (112). How-
ever, both in MPTP-lesioned monkeys (112) and in 6-OHDA rats
(113), l-DOPA increased pAkt and pGSK3. Moreover, increase in
pAkt(Ser473)/Akt and pGSK3β(Ser9)/GSK3β ratios was observed
in the l-DOPA-treated MPTP group, this was prevented with the
addition of MPEP and positive correlations were observed between
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these levels and mean dyskinesia scores (47). This supports a possi-
ble involvement of Akt/GSK3β in the mechanisms associated with
the development of LID. MPEP might prevent changes in this
kinase pathway associated with l-DOPA and could provide new
avenues to probe potential novel targets to treat LID.
This mini review focused on glutamate neurotransmission in
LID and presented some of its interaction with other neuro-
transmitter systems showing the complexity of this motor com-
plication and its treatment. Indeed, altered dopaminergic and
non-dopaminergic neurotransmission, including also serotoner-
gic, adenosine, cannabinoid, opioid, GABAergic, adrenergic, hist-
aminergic, and cholinergic systems are observed in LID (12, 51).
For example, serotoninergic dysfunctions in LID are well docu-
mented (114, 115) and serotonin neurotransmission can interact
with iGlu (116–118) and mGlu receptors (119).
CONCLUSION
Nigrostriatal denervation in PD leads to increased glutamatergic
transmission in the basal ganglia; increased glutamate neurotrans-
mission is also observed in LID. These observations suggest that
glutamate receptor stimulation is involved in the pathogenesis
of l-DOPA-induced motor complications in PD and glutamate
receptor subtypes, such as mGlu5 and NMDA receptors, are poten-
tial selective targets for treatment of these adverse effects. Recent
studies point to changes in activation of DA receptor signaling in
LID rather than changes in DA receptor density. Post-mortem
brains of dyskinetic MPTP-lesioned monkeys and PD patients
treated with anti-glutamatergic drugs and inhibiting LID show
multiple brain molecular changes suggesting various receptors
interactions. Thus, ionotropic and metabotropic glutamate recep-
tors represent interesting targets to reduce and prevent LID as well
as to prevent associated molecular changes beyond their specific
receptor target.
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